In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this "real-life" study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV).
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study / Lionetti, Raffaella; Calvaruso, Vincenza; Piccolo, Paola; Mancusi, Rossella Letizia; Mazzarelli, Chiara; Fagiuoli, Stefano; Montalbano, Marzia; Lenci, Ilaria; Carrai, Paola; Guaraldi, Giovanni; Visco-Comandini, Ubaldo; Milana, Martina; Biolato, Marco; Loiacono, Laura; Valente, Giovanna; Craxì, Antonio; Angelico, Mario; D'offizi, Gianpiero. - In: CLINICAL TRANSPLANTATION. - ISSN 0902-0063. - 32:2(2018), pp. 1-8. [10.1111/ctr.13165]
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study
Guaraldi, Giovanni;
2018
Abstract
In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this "real-life" study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV).
| File | Dimensione | Formato | |
|---|---|---|---|
|
2017 Sofosbuvir and daclatasvir.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
776.32 kB
Formato
Adobe PDF
|
776.32 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
